The 'torsadogenic' property of a drug is linked to its ability to increase the transmural dispersion of repolarisation, represented by the interval between the peak of, and the end of, the T-wave (Tp-e interval) in an electrocardiogram. Reports have consistently shown that sevoflurane does not increase the Tp-e interval. Type 2 diabetes is a risk factor for increased QTc (ratecorrected QT interval), QTcd (rate-corrected QTc dispersion: difference between the maximum and the minimum QTc interval), and Tp-e, as well as the rate-corrected Tp-e (Tp-e/QTc ratio). The study aimed to ascertain whether sevoflurane increased the Tp-e interval and Tp-e/QTc ratio in patients with diabetes, thereby increasing their risk of torsades. We enrolled 35 female patients; 17 with type 2 diabetes and 18 controls undergoing non-laparoscopic surgery under sevoflurane anaesthesia. The Tp-e interval, Tp-e/QTc ratio, QTc and QTcd were recorded after intubation, 5, 10, 30 and 60 minutes into the anaesthetic, and were compared between the groups. No significant increase in the Tp-e interval or Tp-e/QTc was observed between or within the groups (a 13 ms increase was considered significant). In the control group, the QTc was significantly increased from baseline immediately after intubation (449 versus 414 ms, P <0.001); at 5 minutes (434 versus 414 ms, P=0.01); at 10 minutes (444 versus 414 ms, P=0.002); at 30 minutes (439 versus 414 ms, P=0.001) and at 60 minutes (442 versus 414 ms; P <0.001) (a 20 ms increase was considered significant). No significant increase in QTc was observed in the diabetic group. There were no between or within group differences observed for QTcd. Our findings suggest that sevoflurane does not have a significant predictable pro-arrhythmic effect in type 2 diabetic patients in the absence of other factors affecting ventricular repolarisation.
Introduction
Sevoflurane causes a drug-induced acquired increased QTc (rate-corrected QT interval) [1] [2] [3] . This reflects a prolonged ventricular depolarisation and repolarisation, which in its most lethal form can be associated with torsades de pointes (TdP). Although prolongation of QTc and QTcd (difference between maximum and minimum QTc) are generally considered as risk factors for the development of ventricular arrhythmias, they are not the most accurate indices in assessing drug-induced TdP 4, 5 . The interval from the peak to the end of the T-wave (Tp-e interval) of the electrocardiogram (ECG) seems to be more reliable in predicting the torsadogenic property of a drug 4 . Tp-e represents the transmural dispersion of repolarisation (TDR); prolongation of this interval increases the risk of TdP 4 . TDR is a physiological phenomenon of asynchronous repolarisation across the myocardial wall (epicardium, M cells and endocardium) 3 . Since Tp-e is heart rate-dependent, constant parameters such as the Tp-e/QT and Tp-e/QTc ratios have been utilised as surrogate indices of TDR in healthy as well as diabetic populations, predicting the risk of TdP 4, 6 . Current evidence suggests that sevoflurane does not affect the Tp-e interval, exerting no influence on TDR 3, [7] [8] [9] . In diabetic patients, both acute hyperglycaemia and autonomic dysfunction have been shown to prolong the QTc [10] [11] [12] . The TDR indices of Tp-e and Tp-e/QTc have also been shown to be elevated in patients with type 2 diabetes (T2DM) 6, 13 . There are no data about the influence of sevoflurane on TDR in diabetic patients. We have previously reported a case of TdP under sevoflurane anaesthesia in a patient with poorly controlled diabetes 14 where we hypothesised that diabetic patients may be susceptible to changes in TDR with sevoflurane exposure. Recently, there has been greater emphasis on the significance of preexisting preoperative QTc prolongation. Data from three studies (combining nearly 1,600 patients) has shown that pre-existing QTc prolongation is an independent risk factor for major postoperative adverse cardiovascular events [15] [16] [17] . Indeed, a 13% increase in these adverse events was noted for every 10 ms increase in QTc interval over 436 ms 15 . Up to one-fourth of T2DM patients exhibit QTc prolongation 18 . The aim of this study was to investigate whether sevoflurane in clinically relevant doses had a predictable effect on the TDR indices, namely Tp-e and Tp-e/QTc in patients with T2DM.
Methods
The study was a prospective, single-centre, observational study performed over a four-year period. The protocol was developed in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting observational studies and was approved by the ethics committee of Central Adelaide Local Health Network (HREC reference no: 2010036); the study was registered at the Australian New Zealand Clinical Trials Registry, ACTRN: 12610000259044.
Thirty-five female patients (17 diabetics and 18 controls) were recruited to this study after obtaining informed consent. All were classified as American Society of Anesthesiologists (ASA) physical status I-III, scheduled for elective nonlaparoscopic surgical procedures lasting more than 60 minutes requiring general anaesthesia with endotracheal intubation. In the diabetic group, patients had a minimum duration of treatment (with oral hypoglycaemic agents +/-insulin) of two years or had at least one HbA1c level more than 53 mmol/mol (7%) recorded prior to the presentation. A similar number of non-diabetic patients formed the control group. The patients were prospectively enrolled to either the diabetic group or the control group.
Patients were excluded with: a preoperative QTc interval greater than 460 ms, conduction defects and arrhythmias, medications affecting the QTc interval, ischaemic heart disease as defined by previous history of angina, myocardial infarction or ischaemic cardiomyopathy, patients with congenital or acquired cardiac valvular defects, preexisting electrolyte imbalances, hypo-or hyperthyroidism, renal dysfunction as defined by an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 or active liver disease (alanine aminotransferase >45 U/l or aspartate aminotransferase >55 U/l). Diabetic patients on diet control and those with known or suspected family history of malignant hyperthermia were also excluded. Preoperative magnesium levels were checked in all patients.
Anaesthetic management was standardised for both groups. None of the patients were premedicated. Monitoring consisted of ECG, pulse oximetry, non-invasive blood pressure, temperature, and bispectral index monitor (BIS). After preoxygenation for three minutes, anaesthesia was induced with 2 µg/kg of fentanyl and 3-4 mg/kg of propofol, and either vecuronium 0.1 mg/kg or rocuronium 0.6 mg/kg was used to facilitate endotracheal intubation. The patients' lungs were manually ventilated for three minutes via a facemask using 100% O 2 and 2% expiratory concentration of sevoflurane at a fresh gas flow of 6 litres per minute. After tracheal intubation, mechanical ventilation was continued using the S/5 ADU TM (Datex Ohmeda TM , Bromma, Sweden) anaesthesia system to maintain normocapnia. A fresh gas mixture of oxygen/air with an FiO 2 of 0.5 at 1.5 litres per minute was used throughout the procedure. The end-tidal concentration of sevoflurane was maintained to an age-adjusted minimum alveolar concentration between 0.8 and 1.0. The bispectral index was maintained between 40 and 60 throughout the study period using incremental changes in sevoflurane as described with additional doses of fentanyl if required. One gram of intravenous paracetamol was given. The blood sugar level was measured at hourly intervals and maintained between 6-9 mmol/l using insulin and a dextrose infusion in the diabetic group. Antiemetics were only administered after the study period and muscle relaxation was reversed with neostigmine and glycopyrrolate prior to extubation.
The ECG was recorded using the Philips Intellivue monitoring system (Philips Healthcare, North Ryde, New South Wales). A modified 12-lead ECG derived from five electrodes (EASI TM system, Philips Healthcare, North Ryde, New South Wales) was used throughout the study. A 12-lead ECG and a set of haemodynamic parameters (heart rate [HR] and mean arterial blood pressure [MAP] ) were recorded before induction of anaesthesia (baseline), after intubation, and at 5, 10, 30 and 60 minutes. The participant's involvement in the study was deemed complete at 60 minutes. The following cardiographic parameters were analysed: a] QTc; b] QTc dispersion (QTcd); c] Tp-e interval (Tp-e); and d] Tp-e/ corrected QTc interval ratio (Tp-e/QTc).
QT interval was measured manually in lead II from the beginning of the QRS complex to the end of the T wave. Correction of the QT interval was based on Bazett's formula which is QT interval divided by the square root of the R-R interval in seconds. QTc values greater than 460 ms were considered to be prolonged. QTcd was calculated after measuring the QTc interval in all the leads.
Tp-e interval was measured in lead V2 from the peak of the T-wave to the end of the T-wave. The end of the T-wave was defined as the point of return to the T-P baseline. The mean value of three successive cardiac cycles was used for statistical analysis. Callipers and magnifiers were used to aid ECG measurement. Two investigators (VT and LD) analysed the ECG measurements without the knowledge of the group allocation. If the inter-observer difference was >20 ms for the QTc and the Tp-e interval, the analysis was repeated and a consensus obtained. Two values of the mean for each parameter were obtained, one from each investigator. These values were then averaged to obtain an overall mean value for analysis.
The primary outcome measures were the changes in Tp-e interval and Tp-e/QTc ratio between the groups and within the groups with regard to the baseline at the pre-specified timepoints. Secondary outcome measures included changes in QTc and QTcd values between the groups and within the groups with regard to the baseline during the study period.
Statistical analysis
The calculated sample size requirement was 34 (17 per group) for an alpha level of 0.05 and a power of 90% to detect a mean difference in the QTc interval of 20 ms between the groups. This calculation was based on population data by Benhorin et al 19 giving the mean (standard deviation, SD) of QTc interval as 414 (17) ms from 315 normal patients. When the study was designed, there was no population data available for Tp-e interval or rate corrected Tp-e in diabetic patients, and hence, it was powered to the secondary outcome. Nonetheless, an interim power analysis with emerging data on the primary outcome revealed that a sample size of 24 (12 per group) would be required assuming an alpha level of 0.05 and a power of 90% to detect a mean difference in the Tp-e interval of 13 ms between the groups. This calculation was based on a population study giving the mean (SD) of Tp-e interval as 79.4 (10.3) and 66.4 (8.1) ms in type 2 diabetic patients and controls respectively 6 . Data were expressed as mean (SD) or 95% confidence intervals (CI). Statistical analysis was performed using STATA 14.1 statistical software (StataCorp LP, College Station, TX, USA). Comparisons of baseline and intraoperative ECG parameters were performed between the two groups as well as within group changes over time using unpaired and paired Student's t-test respectively. To account for multiple testing in five successive timepoints, we used the Bonferroni correction. Statistical significance was achieved if the P-value was less than 0.01 (= 0.05/5). Given an α level of 0.01, we report 95% confidence intervals of the ECG parameters.
Results
Thirty-five patients were recruited to the study, 17 in the diabetic group and 18 in the control group. Table 1 shows the demographic characteristics and baseline ECG parameters and haemodynamic variables of the two groups. Among the diabetic patients, 11 were on a single oral hypoglycaemic agent (OHA), three were on dual OHAs, and three were on OHA plus insulin. The mean HbA1c value was 60 mmol/mol (7.7%) (SD 0.5 mmol/mol [2.2%]; range 38-124 mmol/mol [5.6%-13.5%]). Diabetic patients were significantly older than the controls (P=0.01); the baseline haemodynamic parameters were similar between the two groups ( Table 1) .
Tp-e and Tp-e/QTc
The baseline Tp-e and Tp-e/QTc values were similar in the two groups. While there was an observable elevation and a greater variability of Tp-e and and Tp-e/QTc noticed during the study in the diabetic group, at no time interval did this reach significance (Figure 1 ). Values are mean (standard deviation); QTc, rate corrected QT interval; QTcd, difference between maximum and minimum QTc; Tp-e, T peak-end interval. 
QTc and QTcd
The baseline QTc and QTcd values were elevated in the diabetic group, however, the difference was insignificant. In the control group, the QTc was significantly increased from baseline soon after intubation (P <0.001); at 5 minutes (P=0.01); at 10 minutes (P=0.002) and at 60 minutes (P <0.001). There was a slight non-significant increase of QTc in the diabetic group. No significant within-group difference or between-group difference was observed for QTcd ( Figure 2 ).
Other variables
With respect to the haemodynamic parameters, no significant differences were observed between the groups (Figure 3 ). The variables of BIS and temperature were similar between the two groups (data not shown).
No adverse events were observed during the study.
Discussion
Data from our study show that sevoflurane exposure of clinically relevant doses had no significant impact on the Tp-e interval and Tp-e/QTc ratio in patients with T2DM, implying that TDR remained unaltered (an increase of 13 ms or more was considered clinically significant). Agents not affecting the TDR have little or no potential to provoke arrhythmia, despite being able to prolong the QT interval 20 . Hence, our findings indicate that sevoflurane has a very low intrinsic torsadogenic potency in a cohort of low-risk diabetic patients in the absence of other impediments on the action potential duration. The absence of QTc prolongation observed in our diabetic group is in contrast to the findings from a recent similar study by Kitaura et al 21 (abstract only data). The authors reported a greater QTc prolongation in diabetic patients (recruited with HbA1c >47 mmol/mol [6.5%]) upon sevoflurane exposure at 90 and 120 minutes. Further, a linear regression analysis noticed a good correlation between HbA1c and QTc prolongation at 90 and 120 minutes. While the diabetic patients in the aforementioned study had similar baseline QTc values, we noted a significantly higher QTc in our diabetic sample, and our study terminated at 60 minutes. This might indicate that apart from the wellknown dose-response relationship between sevoflurane and QTc prolongation 22 , duration of exposure may be equally important. There is one point of agreement: both our study and that of Kituara et al showed no change in Tp-e intervals.
The peak of the T wave corresponds to the completion of epicardial repolarisation and the end of the T wave corresponds with the full recovery of M cells 3, 4 . The Tp-e interval normally ranges between 40 and 110 ms; values beyond 117 ms significantly predict the occurrence of TdP 23, 24 . Across five different timepoints, the largest mean Tp-e in our diabetic group was 109 ms (after intubation). The control group showed no changes in the Tp-e. A similar Tp-e-sparing effect has been consistently reported in patients across all age groups up to 1.5 minimum alveolar concentration sevoflurane administration even with concomitant use of another QT prolonging agent such as ondansetron 3, [7] [8] [9] . The normal limit for Tp-e/QTc ratio is 0.16-0.22 25 . While a TdP threshold for Tp-e/QTc ratio is not known, values of Tp-e/ QT >0.28 have been correlated to TdP; therefore, a similar limit is probably applicable for the Tp-e/QTc ratio as well 4 . The aforementioned TDR parameters have been found to be elevated in patients with T2DM; with a 7.3% prevalence of prolonged Tp-e interval reported in population studies 6, 13 . Also, it has been noted that HbA1c and blood glucose levels have discrete positive correlations with Tp-e and Tp-e/QTc ratio 6 . The highest mean Tp-e/QTc seen in the diabetic group during the study was 0.24. The mean values for baseline Tp-e and Tp-e/QTc were within normal limits in the diabetic group. Likewise, the highest mean values reached during the study were well within the torsadogenic thresholds. It is conceivable that pre-existing TDR changes were less pronounced in the diabetic group as a result of strict selection criteria excluding all confounding factors affecting the QTc interval.
The prolongation of the QTc interval (>20 ms) observed in our control group, as compared to the baseline, is in keeping with numerous studies that have shown a propensity for sevoflurane to prolong the QTc interval in healthy individuals in the absence of premedication irrespective of age [1] [2] [3] [26] [27] [28] [29] . Even this issue is not entirely settled however, as some studies have shown that sevoflurane maintenance does not affect the QTc interval [30] [31] . The literature is also inconsistent in regard to sevoflurane's effect on QTcd with some studies showing an increase [32] [33] [34] , and others showing a decrease 35 . In our study, in contrast to the increases in QTc interval, an overall neutral effect was observed for QTcd in both the groups compared to baseline. The wide confidence intervals for the diabetic group throughout the study period for all outcome measures may suggest a predominantly higher within-group variation.
Surprisingly, the well-described intubation-induced QTc interval prolongation 36, 37 , as well as an increase in heart rate post-intubation, while observed in the control group was not evident in the diabetic group. A diminished heart rate response after intubation has been noted previously in diabetic patients with proven autonomic neuropathy 38 .
In the absence of formal preoperative testing of autonomic neuropathy in our diabetic patients, we could merely speculate that these attenuated post-intubation responses may be reflective of pre-existing autonomic neuropathy.
The baseline values of QTc and QTcd were higher in our diabetic group. A population-based study on T2DM reported a prevalence of prolonged QTc and QTcd as 25% and 33% respectively, with a strong independent correlation of coronary heart disease to these indices 18 . These changes, alerting the presence of cardiac autonomic neuropathy 12 , can manifest within one year of diagnosis in type 2 and within 2 years in type 1 diabetes 39 . Only type 2 diabetic patients were enrolled in this study, however, we would expect similar findings in type 1 diabetic patients.
In a prospective study of 469 patients undergoing noncardiac procedures, up to 48 hours into the postoperative period it was evident that minor QTc interval prolongation (an average of 23 ms) was noted in 80% of the patients. This paper described a QTc over 440 ms in 51%, with a noted incidence of 4% of marked QTc prolongation (>500 ms) and with one patient developing TdP 40 . The same study revealed that 39% of patients exposed to sevoflurane had significant QTc prolongation (>30 ms). Data from another observational study revealed that the presence of diabetes may be a predominant risk factor for perioperative prolongation of QTc interval regardless of the anaesthetic technique 41 . It has to be noted however, that both these studies failed to analyse the torsadogenic parameters such as Tp-e and Tp-e/QTc ratio 40, 41 . A systematic review of published reports of perioperative TdP showed that perioperative TdP occurred when there was an increase in the QTc of >100 ms compared with the baseline, and a mean QTc of 575 ms was noted during the time of the TdP event 42 . In the non-perioperative setting a QTc exceeding 500 ms is considered a significant risk factor for TdP 4 . Considering the above values as possible torsadogenic thresholds, five of our diabetic patients had a QTc increase of over 100 ms from baseline; two of them had QTc over 575 ms and nine out of seventeen (53%) diabetic patients had at least one value of QTc over 500 ms during the study. Notably, only three of our diabetic patients were on insulin, yet, they all had suboptimal glycaemic control with a mean HbA1c of 60 mmol/mol (7.7%) (range 38-124 mmol/mol [5.6%-13.5%]). Available data suggest that poor preoperative glycaemic control is an independent predictor of adverse perioperative outcome 43, 44 . Ventricular repolarisation abnormalities in diabetics are attributed to neurohormonal and metabolic imbalances. These induce structural changes in the myocardium secondary to a multitude of co-existing factors such as coronary artery disease, hypertension, neuropathy, nephropathy, cardiac failure, altered blood sugar levels, and dyslipidaemias 6, 13 . Sevoflurane exposure alone may not trigger a malignant arrhythmia in diabetics as TdP occurrence is multifactorial. With respect to perioperative QTc prolongation, drug interaction seems to play a major role 40 . Automated QTc measurements are available in real time in most of the intraoperative monitors and recording the baseline QTc value and continuous monitoring of both QTc and TDR parameters may be possible. In patients with poor glycaemic control and who have additional risk factors, increased vigilance of the torsadogenic indices, Tp-e interval and Tp-e/QTc ratio, may be warranted. Avoiding unnecessary polypharmacy is always worthwhile.
Our study has several limitations. The QT parameters were analysed using the 12-lead ECG derived from EASI leads, and not from a standard 12-lead ECG. Nevertheless, clinically it has been proven that QT measurements from an EASI-derived 12-lead ECG are comparable to that of a standard 12-lead ECG 45 . Only female patients were included in the study. QTc is longer in women and they are more prone to drug-induced interval changes and thus more vulnerable to arrhythmias 46 . We favoured a more homogeneous group of participants and feel that similar less extensive changes would be observed in a male population. The diabetic patients were significantly older than their counterparts and an age adjustment was not done while analysing the results. Future studies evaluating this association should involve more subjects with coexisting elements for acquired QTc prolongation such as mono/polytherapy with QTc-prolonging agents and clinical conditions that are likely to impact ventricular repolarisation.
Conclusion
Sevoflurane does not appear to prolong Tp-e and Tp-e/ QTc in patients with type 2 diabetes, indicating that the transmural dispersion of repolarisation remains unaffected. This may suggest that sevoflurane has no predictable torsadogenic property in patients with type 2 diabetes in the absence of other QTc-prolonging elements. Yet, these negative results from a small population of relatively stable diabetic patients have to be interpreted with caution, as the high prevalence of pre-existing QTc abnormalities in diabetic patients itself is a significant predictor of postoperative adverse cardiac events.
